A phase 2 study evaluating the efficacy and safety of neoadjuvant sintilimab, albumin-bound paclitaxel, and carboplatin in locally advanced esophageal squamous cell carcinoma (ESCC).
Latest Information Update: 15 Jul 2024
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Sintilimab (Primary)
- Indications Carcinoma; Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 15 Jul 2024 New trial record
- 04 Jun 2024 Results( November 2020 to November 2021, n=24) presented at the 60th Annual Meeting of the American Society of Clinical Oncology